search
Back to results

Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease

Primary Purpose

Parkinson's Disease

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Donepezil
Sugar Pill (placebo)
Sponsored by
Oregon Health and Science University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson's Disease focused on measuring parkinsons disease, falling

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age over 21
  • Diagnosis of Parkinson's disease
  • Treated with dopaminergic medication for at least 1 year

Exclusion Criteria:

  • Must be ambulatory (can use walker or cane)
  • No obvious remediable cause of falls
  • Falls are on basis of non-CNS etiologies (cardiogenic, orthopedic, peripheral neuropathy, etc)
  • Dementia present (MMSE < 25)
  • Not taking cholinergic or anticholinergic medications 10 days prior to screening visit
  • No Warfarin use

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Donepezil

    Sugar Pill

    Arm Description

    Outcomes

    Primary Outcome Measures

    Fall Frequency Per Day
    The primary outcomes were fall frequency determined using daily event recording by the subjects onto postcards which accumulated data for six weeks per phase. Falls were defined as landing on the floor. Fall frequency is the number of reported falls divided by the number of days reported. Postcards were mailed back to the investigator weekly.

    Secondary Outcome Measures

    Frequency of Near Falls Per Day
    The secondary outcome was near fall frequency determined using daily event recording by the subjects onto postcards which accumulated data for six weeks per phase. Near falls were defined as a fall that did not land on the floor (for example grabbing a handrail or a table). Near fall frequency is the number of reported near falls divided by the number of days reported. Postcards were mailed back to the investigator weekly.

    Full Information

    First Posted
    June 2, 2009
    Last Updated
    April 5, 2018
    Sponsor
    Oregon Health and Science University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00912808
    Brief Title
    Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease
    Official Title
    A Study of Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    October 2005 (undefined)
    Primary Completion Date
    February 2009 (Actual)
    Study Completion Date
    February 2009 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Oregon Health and Science University

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to find out if a medication that increases levels of a brain chemical called acetylcholine will improve balance and reduce falls in patients with parkinson's disease who have the problem of very poor balance and are frequently falling or nearly falling on a daily basis. Donepezil, a drug approved for the treatment of Alzheimer's dementia, will reduce falls in subjects with Parkinson's disease and balance impairment.
    Detailed Description
    This trial is a double-blinded cross-over design comparing donepezil with placebo in 40 subjects with idiopathic Parkinson's disease who report frequent falls or near falls (>2/week). The purpose of this study is to find out if a medication that increases levels of a brain chemical called acetylcholine will improve balance and reduce falls in patients with parkinson's disease who have the problem of very poor balance and are frequently falling or nearly falling on a daily basis. Donepezil, a drug approved for the treatment of Alzheimer's dementia, will reduce falls in subjects with Parkinson's disease and balance impairment.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Parkinson's Disease
    Keywords
    parkinsons disease, falling

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Crossover Assignment
    Masking
    InvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    23 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Donepezil
    Arm Type
    Experimental
    Arm Title
    Sugar Pill
    Arm Type
    Placebo Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Donepezil
    Other Intervention Name(s)
    aricept
    Intervention Description
    donepezil, 5 mg, capsule, once a day, 3 weeks
    Intervention Type
    Drug
    Intervention Name(s)
    Sugar Pill (placebo)
    Intervention Description
    sugar pill, one capsule, once a day, 3 weeks
    Primary Outcome Measure Information:
    Title
    Fall Frequency Per Day
    Description
    The primary outcomes were fall frequency determined using daily event recording by the subjects onto postcards which accumulated data for six weeks per phase. Falls were defined as landing on the floor. Fall frequency is the number of reported falls divided by the number of days reported. Postcards were mailed back to the investigator weekly.
    Time Frame
    6 weeks
    Secondary Outcome Measure Information:
    Title
    Frequency of Near Falls Per Day
    Description
    The secondary outcome was near fall frequency determined using daily event recording by the subjects onto postcards which accumulated data for six weeks per phase. Near falls were defined as a fall that did not land on the floor (for example grabbing a handrail or a table). Near fall frequency is the number of reported near falls divided by the number of days reported. Postcards were mailed back to the investigator weekly.
    Time Frame
    6 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    21 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age over 21 Diagnosis of Parkinson's disease Treated with dopaminergic medication for at least 1 year Exclusion Criteria: Must be ambulatory (can use walker or cane) No obvious remediable cause of falls Falls are on basis of non-CNS etiologies (cardiogenic, orthopedic, peripheral neuropathy, etc) Dementia present (MMSE < 25) Not taking cholinergic or anticholinergic medications 10 days prior to screening visit No Warfarin use
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Kathryn Chung, MD
    Organizational Affiliation
    Oregon Health and Science University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease

    We'll reach out to this number within 24 hrs